课题基金 / 基金详情

Clinical Sample Database and Proteomics

Clinical Sample Database and Proteomics
临床样本数据库和蛋白质组学
批准号：
8000928
负责人：
Sophie Paczesny
金额：
$17.35万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
项目状态：
已结题
起止时间：
2010-07-01 至 2015-06-30
来源：
https://reporter.nih.gov/project-details/8000928
关键词：
Allogeneic Bone Marrow TransplantationAllogenicArchivesBiological MarkersCharacteristicsClinicalClinical DataClinical ResearchCollectionComplicationDataData QualityDatabasesDevelopmentDiseaseEnsureEventHematopoietic Stem Cell TransplantationIndividualInstructionLinkMalignant - descriptorMalignant NeoplasmsModalityOutcomePatientsProcessProductivityProteinsProteomicsQuality ControlResearchResearch SupportSamplingServicesTechnologyTherapeuticTimeValidationcomputerized data processinggraft vs host diseaseprogramssample collection

项目摘要

项目成果

Sophie Paczesny的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMIVIARY (See instructions): Core C will provide support for research sample collection for BMT patients and ensure proper and consistent quality control regarding the collection, processing, archiving and distribution of samples. Core C will also ensure quality control of the clinical status and endpoints of individuals whose samples are collected and analyzed. In addition, Core C will continue to support exploratory proteomic profiling of clinical research samples from allogeneic BMT patients. During this last cycle. Core C has been instrumental in the development and validation of a four biomarker panel of GVHD. The services provided by Core C will include the following: 1. To collect, process, store, and distribute patient derived research samples 2. To collect data for, quality control, and maintain the integrated comprehensive patient database 3. To provide cutting edge proteomic analysis technology
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chronic Graft-Versus-Host Disease Biomarkers: Prediction of Resistance to Therapy
IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients
IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease
海外基金